Navigation Links
Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting
Date:12/6/2008

act will break at that time.

Results from this multinational phase III study demonstrate that the combination of fludarabine, cyclophosphamide, and rituximab (FCR) provides a 10-month improvement in progression-free survival and a near doubling of complete response rates in patients with relapsed or refractory chronic lymphocytic leukemia.

A total of 552 patients from 17 countries with relapsed or refractory chronic lymphocytic leukemia were randomized to receive six 28-day cycles of fludarabine (25 mg/m^2 intravenously on days 1 to 3) and cyclophosphamide (250 mg/m^2 intravenously on days 1 to 3) alone (FC) or in combination with rituximab (FCR) (375 mg/m^2 rituximab intravenously at the start of first cycle and 500 mg/m^2 on day 1 for all subsequent cycles). Patients previously had received an average of one previous treatment regimen, including a single-agent alkylator therapy (66 percent), a purine-analog therapy (16 percent), or combination chemotherapy treatments (18 percent). The primary endpoint of the study was progression- free survival.

Patients in the FCR arm achieved a 30.6-month progression-free survival compared with 20.6 months in the FC arm, translating into a significant 10-month increase in progression-free survival for FCR combination therapy. The overall response rate was significantly higher in the FCR arm (70 percent) as compared with the FC arm (58 percent), because of superior complete-response rates in the FCR arm (24 percent versus 13 percent, respectively). While median overall survival in the FC arm was reached at 53 months, it had not yet been reached in the FCR arm.

While Grade 3 and 4 adverse events were more prevalent in the FCR arm (80 percent) as compared with the FC arm (74 percent), serious adverse events were similar in each treatment arm (50 percent versus 48 percent, respectively). Overall, the FCR combination showed a favorable risk-benefit pr
'/>"/>

SOURCE American Society of Hematology
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
2. New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nations Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. University of Kansas Medical Center to Deploy Velos eResearch System-Wide
5. U.S. Naval Medical Research Center Resubmits IND Application for Proposed Op RESUS Clinical Trial in Trauma Patients in the Battlefield Setting
6. Dominos Pizza Pledges Support to the Fifth Annual St. Jude Childrens Research Hospital(R) Thanks and Giving(R) Campaign
7. Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects
8. Miami Jewish Home and Hospital, Berma Research Group and Segal Institute for Clinical Research Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimers Disease
9. Sarah Cannon Research Institute Selects OmniComm Systems Electronic Data Capture Solution, TrialMaster(TM), for Clinical Trials Management
10. Michael J. Fox Foundation Announces $11 Million in 2009 Funding for Translational, Pre-Clinical and Clinical Parkinsons Disease Research
11. SELECT TRIAL Used Selenomethionine Instead of High-Selenium Yeast, SelenoExcell(R) - Previous Research has Shown SelenoExcell(R) Supplementation to Reduce Lung, Colon and Prostate Cancers by as Much as 63%, Says Cypress Systems, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 17, 2014  ImmunoCellular Therapeutics, Ltd. ... Patent and Trademark Office (USPTO) has issued a ... dendritic cell-based immunotherapeutic vaccine targeting six tumor antigens ... of US Patent No. 8,871,211, which issued October ... by administering a dendritic cell composition comprising peptide ...
(Date:12/17/2014)... 2014 PCCA received the Autism Hope ... ) program seal for best practices in meeting ... medical practices, materials and goods that meet strict ... Children affected by autism often have unique physical ... ingredients found in food and medicine – for ...
(Date:12/15/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/32cmct/inferior_vena ... Vena Cava (IVC) Filters - Global Trends, Estimates and ... http://photos.prnewswire.com/prnh/20130307/600769 Global Inferior ... US$435 million by 2016. The North America ... global value while Europe claims ...
Breaking Medicine Technology:ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 2Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 2Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 4
(Date:12/19/2014)... After a 13-year absence from active ... to the stage to entertain his many worldwide fans. ... and the successful tour has been steadily expanding since ... Visit Ticketability.com for a large inventory of ... fair prices. , Music fans have had a long ...
(Date:12/19/2014)... News) -- A new study suggests a possible link ... flashes and night sweats -- and higher rates of ... common during menopause, affecting about 60 percent of women. ... menopause, since they then face a higher risk of ... who exhibit moderate or severe menopausal symptoms are more ...
(Date:12/19/2014)... (HealthDay News) -- Prostaglandin analogue eye drops -- a ... risk of vision loss in patients with the eye ... by David Garway-Heath, of the Moorfields Eye Hospital and ... more than 500 people newly diagnosed with open-angle glaucoma ... one of the leading causes of blindness. About ...
(Date:12/17/2014)... Providence, RI (PRWEB) December 17, 2014 ... nationally recognize private practices that have made outstanding ... and in support and progression of private practice ... the American Physical Therapy Association. , On behalf ... DPT, OCS, owner and CEO of Performance accepted ...
(Date:12/17/2014)... Crest Hill, IL (PRWEB) December 17, 2014 ... of 2015 Awards celebrate the best of the best ... States. The award is only given to communities and ... families through the SeniorAdvisor.com site. Of the nearly 100,000 ... with this award. Winners of the SeniorAdvisor.com Best of ...
Breaking Medicine News(10 mins):Health News:Garth Brooks Tickets for Joe Louis Arena: Ticketability.com Becomes a Popular Destination for Discount Tickets for Garth Brooks’ Detroit Concerts Set for February 27-28 2Health News:Severe Hot Flashes During Menopause May Raise Hip Fracture Risk Later: Study 2Health News:Study Supports Benefit of Widely Used Glaucoma Drug 2Health News:Performance Physical Therapy Awarded with Jayne L. Snyder Private Practice of the Year 2014 2Health News:The Inn at Willow Falls - Crest Hill, IL Wins 2015 Best of Assisted Living Award from SeniorAdvisor.com 2Health News:The Inn at Willow Falls - Crest Hill, IL Wins 2015 Best of Assisted Living Award from SeniorAdvisor.com 3
... risk of developing leukemia as a side effect of a ... according to a study presented as part of the Late-breaking ... Meeting in Seattle, April 25 - May 2, 2009.Mitoxantrone is ... several forms of advancing MS. It is one of only ...
... manage stress at work and in their homes is ... million National Institutes of Health grant that will also ... reduce employee stress and promote well-being., "We,re seeing that ... that can increase stress and reduce quality of life ...
... related art ROSEMONT, Ill., April 30 Wartime experiences not ... the physicians and medical teams who treat them. As ... orthopaedic surgeons who are caring and have cared for them, ... (AAOS) is opening the call for entries to a unique, ...
... Patients in Many Markets, Dayton , ... Area Quick-Clinic Void with Kroger Partnership, ... HealthLeaders-InterStudy, a leading provider of managed care market intelligence, ... across the country, they have not taken off in the ...
... the immune system attacks the body,s own material just as ... MS for short, is just one such autoimmune disease, and ... 20 to 30 years age group. The disease can have ... attack the central nervous system. It has long been assumed ...
... Inc. today announced that Chris Streng, Vice President, Finance ... been elected to the Codexis Board of Directors, bringing ... Houston, Texas, where he is employed by Shell Downstream ... petrochemical plants in the Shell Group worldwide. He ...
Cached Medicine News:Health News:Risk of Leukemia with Multiple Sclerosis Drug Higher Than Thought 2Health News:Penn State plays integral role in $35 million stress project 2Health News:War and Musculoskeletal Injury Prompt Artistic Expression 2Health News:War and Musculoskeletal Injury Prompt Artistic Expression 3Health News:Physician-Led Quick-Care Clinics Protect Patient Base 2Health News:Physician-Led Quick-Care Clinics Protect Patient Base 3Health News:Gray matter under attack in multiple sclerosis 2Health News:Gray matter under attack in multiple sclerosis 3Health News:Shell Finance Executive Streng Elected to Codexis Board 2
Amylase (EPS-G7, kinetics), Wavelength: 405 nm. Linear range; 5-1500 IU/L....
g-GT Liquid Reagent (Kinetic Method). Wavelength: 405 nm. Linear range: 0-200 U/mL. Prepare Working Reagent in the ratio of 5 parts R1 to 1 part of R2, (i.e., 50 mL R1 and 10 mL R2)....
Intended for the quantitative determination of calcium in serum. Endpoint Reaction. Reaction complete within one minute, color developed is stable for 30 minutes. Wavelength: 570 nm. Linearity: 16 mg...
... the quantitative determination of alanine ... plasma. Two vials, dry powder ... be purchased separately for conformity ... Wavelength: 340 nm. Linearity: 268 ...
Medicine Products: